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Abstract
Mucormycetes infections are very difﬁcult to treat and a delay in diagnosis could be fatal for the outcome of the patient. A molecular
diagnostic technique based on Real Time PCR was developed for the simultaneous detection of Rhizopus oryzae, Rhizopus microsporus
and the genus Mucor spp. in both culture and clinical samples. The methodology used was Molecular beacon species-speciﬁc probes with
an internal control. This multiplex real-time PCR (MRT-PCR) was tested in 22 cultured strains and 12 clinical samples from patients suf-
fering from a proven mucormycosis. Results showed 100% speciﬁcity and a detection limit of 1 fg of DNA per microlitre of sample.
The sensitivity was 100% for clinical cultured strains and for clinical samples containing species detected by the PCR assay. Other mu-
cormycetes species were not detected in clinical samples. This technique can be useful for clinical diagnosis and further studies are war-
ranted.
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Introduction
Mucormycosis is an important emerging fungal infection asso-
ciated with high morbidity and mortality [1]. Infections
caused by fungi belonging to the Mucorales order occur in
immuno-compromised patients or those with chronic debili-
tating conditions such as ketoacidosis or uncontrolled diabe-
tes mellitus, among others. It is a devastating fungal infection
that progresses quickly and has a very poor prognosis due
to the resistance of Mucormycetes to the newer antifungal
agents, such as voriconazole and caspofungin [2].
The incidence of these infections has increased in the last
decades as they have been reported from institutions in Eur-
ope and the USA [3,4]. The change in the epidemiology has
been associated with widespread use of voriconazole or
caspofungin [5] for the treatment of invasive aspergillosis, as
these fungi are resistant to such antifungal drugs, although it
remains unclear whether there is genuine epidemiological
association with voriconazole or whether this is the result of
changes in immunosuppression strategies [4,6]. The treat-
ment of these mycoses is based on a combination of three
types of measures: surgical resection, treatment with high
doses of antifungal drugs and adjuvant therapies to control
the underlying conditions that promote infection. Of the
three measures, surgery is the most crucial and recom-
mended whenever possible [7], given the extremely low
rates of response to medical treatment [8]. The most recent
therapeutic strategies are based on the role of the LAmB,
posaconazole, and the use of adjuvant therapies such as
employing deferaxirox [9].
Species identiﬁcation is essential to choose the most suit-
able antifungal therapy because the different species of
Mucormycetes exhibit different antifungal susceptibility proﬁles
[10–12].
The diagnosis and management of mucormycosis remains
a difﬁcult task; indeed, there are no clinical or radiological
signs speciﬁc to this disease [13]. Classical methods such as
histopathology or direct visualization for observation of the
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characteristic broad, non-septate and irregularly branched
hyphae are not sensitive enough and are unable to identify
the species [14]. Regarding cultures, these fungi are difﬁcult
to recover from cultures of clinical specimens due to con-
current antifungal therapy or to loss of hyphal viability in tis-
sue homogenization prior to culture [15]. Even though
serological tests have been attempted, these are not recom-
mended [16,17]. On the other hand, immunohistochemical
reagents that detect Aspergillus spp. and Mucormycetes in tis-
sue are commercially available (AbDSerotec), but these
methods have their limitations and they are unable to reach
the species level [18]. Finally, the development of molecular
techniques to detect Mucormycetes species is very recent.
Conventional and real-time PCR-based techniques to amplify
DNA from microbiological cultures or tissues have been
reported [13,19–22], targeting multicopy genes such as 28S
rDNA, Cytochrome b or ITS regions. In most cases,
sequencing the amplicon or analysing melting curves was nec-
essary to discriminate the different genera. Molecular tech-
niques help improve the identiﬁcation from cultures and,
when the clinical sample is available, the direct diagnosis of
mucormycosis using these techniques is the fastest method
for appropriate therapy.
In this report, we describe the development of a multiplex
real-time PCR technique (MRT-PCR) to detect DNA from
the most frequents species involved in invasive mucormyco-
sis.
Material and Methods
Control strains
DNA from different strains was used to standardize the
MRT-PCR assay. Isolates were Rhizopus oryzae (CNM-CM-
3020), R. microsporus (CNM-CM-4244) and Mucor circinelloides
(CNM-CM-2437), all of them belonging to the Mould Collec-
tion of the Spanish National Center of Microbiology (CNM-
CM). For the purposes of evaluating Mucor spp. detection,
other species belonging to this genus were included, such as
Mucor circinelloides (CNM-CM-5170), Mucor plumbeus (CNM-
CM-5245), Mucor racemosus (CNM-CM-3862) and Mucor
velutinosus (CNM-CM-5510). The speciﬁcity of this technique
was assessed including other Mucormycetes such as Cunning-
hamella bertholletiae (CNM-CM4907), Lichtheimia corymbifera
(CNM-CM5039 and CNM-CM5256), Apophysomyces elegans
(CNM-CM6522), Rhizomucor pusillus (CNM-CM6144) and Ac-
tinomucor elegans (CNM-CM4894), as well as other fungal
pathogens: Aspergillus fumigatus (CNM-CM-AF237), Scedospo-
rium apiospermum (CNM-CM-3169), Scedosporium proliﬁcans
(CNM-CM-1627), Fusarium solani (CNM-CM-3035), Fusarium
oxysporum (CNM-CM-2914) and Candida albicans (ATCC
64551).
DNA extraction
DNA extraction from cultured strains was performed as
described previously by Tang et al. [23]. DNA extraction
from clinical samples was performed using the QiAmp Tissue
DNA Mini Kit (Qiagen, Izasa, Madrid, Spain) following the
manufacturer’s instructions. Fifty microlitres of elution buffer
was used for elution. Two microlitres of extracted DNA
were used for each PCR reaction. When the biopsies were
embedded in parafﬁn, the parafﬁn was removed by one
lavage with 1.2 mL of xylene followed by two lavages with
1.2 mL of ethanol (96–100%). After incubating the tissue at
37C in order to evaporate the remains of the ethanol,
DNA was extracted in the manner mentioned above.
Primers and probe design
The assay was designed in order to detect the most frequent
species in human disease (genus Mucor and two species of
genus Rhizopus) because we had a limitation of the number
of ﬂuorescent probes able to be detected by the PCR equip-
ment. Primers and molecular beacon probes were designed
on the basis of the nucleotide sequence of the ITS1 ribo-
somal DNA region from strains belonging to the collection
of the Spanish National Center of Microbiology: 15
sequences of R. oryzae (submission ID, 1541001), and 10
sequences of R. microsporus (Submission ID: 1540471) and
the sequence of the ITS2 region for Mucor spp belonging to
the species M. circinelloides (accession numbers, JX094793,
JX09794, JX09795, JX09796, JX09797, JX09798, JX09799,
JX09800), M. racemosus, M. plumbeus and M. velutinosus. (sub-
mission ID, 1541277). Sequences from GenBank were also
used for the design of the probe that targeted Mucor spp.
species (accession numbers, AF412287, AY243947,
AY243943, AF412290, AY243945).
The reason for choosing the ITS1 or ITS2 region as target
was based on the possibility of designing a suitable probe for
each case. The Beacon Designer 5.0 software (Premier Bio-
soft, Palo Alto, CA, USA) was used to design primers and
probes. An internal control was included to ensure that neg-
ative results were not due to non-speciﬁc inhibition of the
PCR assay. The internal control was designed on the basis of
a jellyﬁsh-derived sequence [24]. A pair of primers and a
speciﬁc molecular beacon labelled with Cy5 were designed
(Table 1). The primers ampliﬁed a 105 bp fragment, which
was cloned in a p-GEMt plasmid (Promega, Madrid, Spain) to
use as an internal control template. The minimum amount of
internal control plasmid (pICJF) to be added to the reaction
mix was adjusted in order to prevent the sensitivity of the
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assay being affected. Two fentograms of the internal control
plasmid were included in each assay. The primers and probes
designed were subjected to a blast search in the GenBank
sequence database (http://blast.ncbi.nim.gov/Blast.cgi) and in
the database of the Department of Mycology of the Spanish
National Center for Microbiology (more than 5000 distinct
sequences) to avoid cross-homology with other microorgan-
isms. The primers and probes sequences are shown in
Table 1.
Multiplex real-time PCR assay
PCR reactions were performed in the Light Cycler 480 Sys-
tem (Roche Diagnostics, Mannheim, Germany). The kit 2x
SensiMix DNA (Quantace, Ecogen, Madrid, Spain) was used
according to the manufacturer’s instructions. The PCR reac-
tion (20 lL) contained 0.5 lM of each primer of the Mucor-
mycetes species, 0.25 lM of the internal control primers,
3 mM MgCl2, 0.2 lM R. oryzae and R. microsporus probes,
0.4 lM of Mucor spp.probe, 0.1 lM of internal control
probe, 2 lL of pICJF and 2 lL of DNA extracted from the
sample. The cycling conditions included preincubation at
95C for 10 min and an ampliﬁcation programme of 40
cycles as follows: denaturation, 95C, 15 s; annealing, 50C,
30 s, extension, 72C, 15 s; cooling cycle, 40C, 30 s. Quan-
tiﬁcation standards were run in conjunction with each set of
samples as well as negative controls. Subsequently, a colour
compensation experiment was performed to prevent ‘cros-
stalk’ between dyes.
The sizes of the amplicons generated were 192 bp for
R. oryzae, 187 for R. microsporus and 263 bp for Mucor spp.
DNA. PCR products were subjected to electrophoresis in
2% agarose gels (Pronadisa, Madrid, Spain), and ampliﬁed
fragments were sequenced (ABI Prism 377 DNA sequencer;
Applied Biosystems, Madrid, Spain) to conﬁrm the PCR
results.
Standardization
Standard curves were constructed with PCR results from
ﬁve repetitions of different dilutions of R. oryzae (CNM-CM-
3020), R. microsporus (CNM-CM-4244) and Mucor circinelloides
(CNM-CM-2437) genomic DNA. Dilutions ranged from
20 ng to 2 fg DNA/20 lL of reaction. A line (y = mx + b)
was constructed by plotting the standard curve of log quan-
tity vs. its corresponding CT value, a cycle in which ﬂuores-
cence becomes detectable against background. If this curve
exhibited a linear regression coefﬁcient value of >0.980, the
standard curve was then used to determine sensitivity, pri-
mer efﬁciencies and reproducibility of the assay. In order to
evaluate the speciﬁcity, 2 ng of DNA/20 lL from six species
of mucormycetes as well as other fungal species and human
and mouse genomic DNA were included in the PCR assay
(see Control strains).
MRT-PCR assay on cultured clinical strains
The speciﬁcity of the technique was assessed using 22 strains
belonging to the Department of Mycology of the Spanish
National Centre for Microbiology; six of them were R. oryzae
strains, ﬁve R. microsporus and 11 Mucor spp. (M. plumbeus
(1), M. racemosus (1) and M. circinelloides (9)). These strains
had been previously identiﬁed by molecular methods. Two
microlitres of the extracted DNA were used in each MRT-
PCR reaction.
MRT-PCR on clinical samples from mucormycosis patients
The utility of MRT-PCR for diagnosis of clinical mucormyco-
sis was evaluated through the use of clinical samples. Twelve
biopsies from nine patients with proven mucormycosis were
tested. Proven mucormycosis was considered when the fun-
gus was recovered in culture from a specimen or when the
typical irregular, broad and non-septate hyphae, were visual-
ized by histopathology. The underlying diseases of patients
TABLE 1. Sequences of primers
and probes designed for the multi-
plex real-time PCR assay
Primers and probes
Rhizopus oryzae
Oli Ror1 (f) 5¢ TCTGGGGTAAGTGATTGC 3¢
Oli Ror2 (r) 5¢ GCGAGAACCAAGAGATCC 3¢
Ror- MB1 5¢ Cyan 500-CGCGATAACCAGGAGTGGCATCGATCAAATCGCG-BHQ1 3¢
Rhizopus microsporus
Oli Rmic1 (f) 5¢ CTTCTCAGTATTGTTTGC 3¢
Oli Rmic2 (r) 5¢ ATGGTATATGGTAAAGGG 3¢
Rmic-MB1 5¢ HEX-CGCGATCCTCTGGCGATGAAGGTCGTATCGCG-BHQ1 3¢
Mucor spp.
Oli Mucor1 (f) 5¢ GTCTTTGAACGCAACTTG 3¢
Oli Mucor4 (r) 5¢ CCTGATTTCAGATCAAAT 3¢
Mucor-MB1 5¢ FAM-CGCGATTTCCAATGAGCACGCCTGTTATCGCG-BHQ1 3¢
Jellyﬁsh (ICa)
Oli1-icjf1 (f) 5¢ GCCTGGTGCAAAAATTGCTTATC 3¢
Oli2-icjf2 (r) 5¢ CTAAGACAAGTGTGTTTATGGTATTG 3¢
CIJF-MB 5¢ Cy5-CGCGATGCTGTTCTTCCGCCACTTCCAATCGCG-BHQ2 3¢
f, forward; r, reverse.
aInternal control.
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and the samples analysed are shown in Table 2. Two microli-
tres of DNA from each sample were used for the MRT-PCR
reaction. When the assay was negative, the DNA from sam-
ples was used to amplify the its1 and its2 regions using the
universal primers ITS1 and ITS4 and then sequencing to ver-
ify the result [25].
Results
In vitro standardization of the MRT-PCR technique
The designed MRT-PCR assay speciﬁcally detected R. oryzae,
R. microsporus and the genus Mucor ssp. The sensitivity of this
technique was 1 fg of DNA per microlitre of sample. The
determination coefﬁcient (r2) of the linear regressions
between crossing point values and different dilutions of
genomic DNA was 0.98–0.99 (p <0.01). The average coefﬁ-
cients of variation were 2% for R. oryzae DNA, 2.2% for
R. microsporus DNA and 1.08% for Mucor spp. DNA. The Ct
value for the internal control was 29.62 ± 0.05. The speciﬁcity
of the MRT-PCR assay was 100%. No positive signal was
detected when 2 ng of DNA from other fungi (Aspergillus
fumigatus, Scedosporium apiospermum, Scedosporium proliﬁcans,
Fusarium solani, Fusarium oxysporum and Candida albicans) and
genomic DNA from humans and mice was tested (Promega,
Madrid, Spain). In addition, no cross-reaction was observed
between these Mucormycetes species. Each species was
detected in the corresponding ﬂuorophore channel and
other Mucormycetes such as Cunninghamella bertholletiae,
Lichtheimia corymbifera, Apophysomyces elegans, Rhizomucor
pusillus and Actinomucor elegans gave a negative result.
Real-time PCR assays for cultured clinical strains
Results were positive in all clinical strains tested. The MRT-
PCR assay speciﬁcally detected DNA from six clinical strains
of R. oryzae, ﬁve R. microsporus, nine Mucor circinelloides, one
Mucor racemosus and one Mucor plumbeus. The crossing point
values varied according to the amount of DNA obtained for
each strain.
MRT-PCR assay on clinical samples from Mucormycosis
patients
MRT-PCR was performed on 12 biopsy samples from nine
patients. The source of the samples was very heterogeneous,
depending on the patient’s symptomatology (Table 2). In
terms of patients, the MRT-PCR was positive in all cases in
which the infection was produced by the species included in
the MRT-PCR assay (7/9). The species detected were R. ory-
zae and Mucor spp. No patient was infected with Rhizopus mi-
crosporus. The assay was negative in two cases. The
subsequent ampliﬁcation of ITS regions and sequencing
showed that samples that were negative contained R. pusillus
(Case 1) and C. bertholletiae (Case 9). Fig. 1 shows the ampli-
ﬁcation signals in different channels depending on the species
of Mucormycetes detected: (a) R. oryzae detection in clinical
samples, (b) Mucor spp. detection in clinical samples and (c)
R. microsporus detection in clinical strains. The amount of
DNA obtained for each sample appears in Table 2. None of
the assays presented inhibition. The internal control
was ampliﬁed in all cases. Negative controls were never
ampliﬁed.
Discussion
Molecular techniques have proven to be very useful in the
correct identiﬁcation of fungal species [26]. However, there
are few reports that describe molecular diagnostic methods
based on real-time PCR for Mucormycetes species. Some
authors described a method to detect Mucormycetes species
based on the analysis of the melting curves, but MRT-PCR
approaches have never been described before [19,20].
TABLE 2. MRT-PCR results for
clinical samples from patients with
proven Mucormycosis
Case
Underlying
disease Fungal infection
Sample
(biopsy) PCR result
Amount
DNA ng/ll
1 ND Disseminated Skin Negativea –
Lung Negativea –
2 ND Gastrointestinal Stomach Rhizopus oryzae 83 · 10)5
Mediastine 32 · 10)5
3 Diabetes Sinonasal Nose Rhizopus oryzae 13 · 10)2
4 Autotransplant Disseminated Necropsy Mucor spp. 38 · 10)5
Necropsy 31 · 10)5
5 SOTR Skin/Subcutaneous Skin Rhizopus oryzae 52 · 10)4
6 Polytrauma Subcutaneous Parotid gland Rhizopus oryzae 61 · 10)7
7 Renal failure Lung Lung Rhizopus oryzae 15 · 10)5
8 SOTR Rhinocerebral ND Rhizopus oryzae 15 · 10)7
9 OD Lung Lung Negativeb –
SOTR, solid organ transplant recipient; OD, oncohaematological disease; ND, no data.
aRhizomucor pusillus by using primers its1 and its4 and then sequencing.
bCunninghamella. bertholletiae by using primers its1 and its4 and then sequencing [28].
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Different species of Mucormycetes exhibited varying anti-
fungal susceptibility, hence the importance of correct identiﬁ-
cation [10]. Amphotericin B is the agent of choice to treat
mucormycosis, although some strains of Rhizopus spp. and
Cunninghamella spp. have high MIC values to this drug. Azole
drugs had limited in vitro activity. In a recent study voriconaz-
ole was not active; itraconazole showed a wide range of
MICs and only posaconazole showed good activity for all
species, except for Cunninghamella bertholletiae. Finally, terbi-
naﬁne showed good activity, except for R. oryzae and M. circi-
nelloides [11].
In this context, species identiﬁcation becomes essential
for the proper choice of antifungal. The technique developed
in this work is a single-tube MRT-PCR able to speciﬁcally
detect the most common species causing mucormycosis
from cultures and clinical samples. Designed probes and
primers targeted the ITS regions of rDNA. An internal con-
trol was included in the assay to detect PCR inhibition. The
assay was speciﬁc (100%), had a good sensitivity and repro-
ducibility, and the results were obtained within 2–3 h. The
MRT-PCR developed was ﬁrst tested on 22 clinical strains
belonging to Rhizopus and Mucor genera. All strains yielded
positive results while other control species included in the
assay were negative. Subsequently, the technique was vali-
dated using 12 biopsy samples from nine patients with pro-
ven mucormycosis. The MRT-PCR detected 100% of
infections caused by Rhizopus spp. or Mucor spp. Only sam-
ples from patients one and nine were negative. The DNA
from these samples was ampliﬁed and sequenced using uni-
versal ITS1 and ITS4 primers. The sequence conﬁrmed that
other species were involved in these cases.
To date there have been several publications which
explain multiple ampliﬁcation reactions based on conven-
tional PCR and subsequent product sequencing stages to
attain identiﬁcation [19,20,27,28]. Some of these works
were based on nested PCR that is not recommended for
the diagnostic test as these assays were considered prone
to producing false-positive results [29]. The advantages of
our technique compared with others already published is
that in a single tube and with a single ampliﬁcation it can
detect the most frequent Mucormycetes species causing the
infection without post-ampliﬁcation manipulation. Further-
more, it includes an internal control which ensures that the
ampliﬁcation reaction has not been inhibited. However, this
technique has the limitation of the real time PCR equip-
ments used, because the number of detection channels is
not large and therefore only the most frequent species of
Mucormycetes can be included in the study. In the future
we hope to include new species as technological advances
so allow.
(a) (b)
(c) (d)
FIG. 1. The dependence of ﬂuorescence signal on the number of cycles in multiplex real-time PCR. (a) The signal of Cyan 500 dye with Rhizopus
oryzae-speciﬁc hybridization probe (clinical samples). (b) The signal of FAM dye with Mucor spp.-speciﬁc hybridization probe (clinical samples). (c)
The signal of HEX dye with Rhizopus microsporus-speciﬁc hybridization probe (clinical strains). (d) The signal of Cy5 dye with pICJF-speciﬁc
hybridization probe (clinical samples).
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As the more frequent species in human disease belong to
the Mucor and Rhizopus genera, a molecular method able to
speciﬁcally detect those species in a quick and sensitive way
would enable earlier diagnosis. As quantitative assays, they
may prove useful in monitoring a patient’s general outcome
and response to antifungal therapy.
In conclusion, the multiplex PCR assay developed seems to
be a promising tool to complement the diagnosis techniques
that are currently routinely used in microbiology laboratories.
Molecular diagnosis of invasive mucormycosis is feasible and
studies are needed using a larger sample number.
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